journal article·2021-07-01Open access

Micro-electrode channel guide (µECG) technology: an online method for continuous electrical recording in a human beating heart-on-chip

Roberta Visone, Giovanni S Ugolini, Daniela Cruz-Moreira, Simona Marzorati, Stefano Piazza, Enrico Pesenti, Alberto Redaelli, Matteo Moretti, Paola Occhetta, Marco Rasponi

Biofabrication· Volume 13· Issue 3

Abstract

Abstract Cardiac toxicity still represents a common adverse outcome causing drug attrition and post-marketing withdrawal. The development of relevant in vitro models resembling the human heart recently opened the path towards a more accurate detection of drug-induced human cardiac toxicity early in the drug development process. Organs-on-chip have been proposed as promising tools to recapitulate in vitro the key aspects of the in vivo cardiac physiology and to provide a means to directly analyze functional readouts. In this scenario, a new device capable of continuous monitoring of electrophysiological signals from functional in vitro human hearts-on-chip is here presented. The development of cardiac microtissues was achieved through a recently published method to control the mechanical environment, while the introduction of a technology consisting in micro-electrode coaxial guides allowed to conduct direct and non-destructive electrophysiology studies. The generated human cardiac microtissues exhibited synchronous spontaneous beating, as demonstrated by multi-point and continuous acquisition of cardiac field potential, and expression of relevant genes encoding for cardiac ion-channels. A proof-of-concept pharmacological validation on three drugs proved the proposed model to potentially be a powerful tool to evaluate functional cardiac toxicity.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Neuroscience and Neural Engineering · Cardiac pacing and defibrillation studies · Tissue Engineering and Regenerative Medicine

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (65)

Show source-provided references
1. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development10.1016/s0008-6363(02)00846-5 ↗
2. The future of drug safety testing: expanding the view and narrowing the focus10.1016/j.drudis.2008.11.009 ↗
3. Towards bridging translational gap in cardiotoxicity prediction: an application of progressive cardiac risk assessment strategy in TdP risk assessment of moxifloxacin10.1208/s12248-018-0199-4 ↗
4. Toxicity testing in the era of induced pluripotent stem cells: a perspective regarding the use of patient-specific induced pluripotent stem cell-derived cardiomyocytes for cardiac safety evaluation10.1016/j.cotox.2020.04.001 ↗
5. Comparison of electrophysiological data from human-induced pluripotent stem cell-derived cardiomyocytes to functional preclinical safety assays10.1093/toxsci/kft113 ↗
6. Screening drug-induced arrhythmia events using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays10.1161/CIRCULATIONAHA.112.000570 ↗
7. Cross-site reliability of human induced pluripotent stem cell-derived cardiomyocyte based safety assays using microelectrode arrays: results from a blinded CiPA pilot study10.1093/toxsci/kfy110 ↗
8. Comprehensive translational assessment of human-induced pluripotent stem cell derived cardiomyocytes for evaluating drug-induced arrhythmias10.1093/toxsci/kfw200 ↗
9. Proarrhythmia risk assessment in human induced pluripotent stem cell-derived cardiomyocytes using the maestro MEA platform10.1093/toxsci/kfv128 ↗
10. Human iPSC-based cardiac microphysiological system for drug screening applications10.1038/srep08883 ↗
11. A platform for generation of chamber-specific cardiac tissues and disease modeling10.1016/j.cell.2018.11.042 ↗
12. Human iPSC-derived cardiomyocytes cultured in 3D engineered heart tissue show physiological upstroke velocity and sodium current density10.1038/s41598-017-05600-w ↗
13. Passive stretch induces structural and functional maturation of engineered heart muscle as predicted by computational modeling10.1002/stem.2732 ↗
14. Pneumatic unidirectional cell stretching device for mechanobiological studies of cardiomyocytes10.1007/s10237-019-01211-8 ↗
15. Advanced maturation of human cardiac tissue grown from pluripotent stem cells10.1038/s41586-018-0016-3 ↗
16. Human engineered heart tissue as a versatile tool in basic research and preclinical toxicology10.1371/journal.pone.0026397 ↗
17. Tailoring cardiac environment in microphysiological systems: an outlook on current and perspective heart-on-chip platforms10.4155/fsoa-2017-0024 ↗
18. Beating heart on a chip: a novel microfluidic platform to generate functional 3D cardiac microtissues10.1039/C5LC01356A ↗
19. Biowire: a platform for maturation of human pluripotent stem cell-derived cardiomyocytes10.1038/nmeth.2524 ↗
20. A microscale biomimetic platform for generation and electro-mechanical stimulation of 3D cardiac microtissues10.1063/1.5037968 ↗
21. Engineered cardiac tissues generated in the biowire II: a platform for human-based drug discovery10.1093/toxsci/kfz168 ↗
22. Human engineered heart tissue: analysis of contractile force10.1016/j.stemcr.2016.04.011 ↗
23. Human-iPSC-derived cardiac stromal cells enhance maturation in 3D cardiac microtissues and reveal non-cardiomyocyte contributions to heart disease10.1016/j.stem.2020.05.004 ↗
24. Human induced pluripotent stem cell-derived engineered heart tissue as a sensitive test system for QT prolongation and arrhythmic triggers10.1161/CIRCEP.117.006035 ↗
25. Generation of 3D functional microvascular networks with human mesenchymal stem cells in microfluidic systems10.1039/C3IB40267C ↗
26. Cardiac muscle tissue engineering: toward an in vitro model for electrophysiological studies10.1152/ajpheart.1999.277.2.H433 ↗
27. Two-dimensional monitoring of spiking networks in acute brain slices10.1007/s00221-001-0932-5 ↗
28. Microfluidic device and relative method for the generation and/or culture and/or maturation of three-dimensional cell and/or tissue constructs
29. A new paradigm for drug-induced torsadogenic risk assessment using human iPS cell-derived cardiomyocytes10.1016/j.vascn.2016.12.003 ↗
30. Multi-parametric assessment of cardiomyocyte excitation-contraction coupling using impedance and field potential recording: a tool for cardiac safety assessment10.1016/j.vascn.2016.06.004 ↗
31. Blockers of the slowly delayed rectifier potassium IKs channel: potential antiarrhythmic agents10.2174/1568016033477469 ↗
32. Therapeutic drug monitoring: antiarrhythmic drugs10.1046/j.1365-2125.1998.t01-1-00768.x ↗
33. Electrophysiological characteristics of human iPSC-derived cardiomyocytes for the assessment of drug-induced proarrhythmic potential10.1371/journal.pone.0167348 ↗
34. Organs-on-chips at the frontiers of drug discovery10.1038/nrd4539 ↗
35. Evolution of strategies to improve preclinical cardiac safety testing10.1038/nrd.2015.34 ↗
36. Preclinical cardiovascular risk assessment in modern drug development10.1093/toxsci/kfm026 ↗
37. Micro-electrode arrays in cardiac safety pharmacology10.2165/00002018-200427110-00002 ↗
38. Modeling of LMNA-related dilated cardiomyopathy using human induced pluripotent stem cells10.3390/cells8060594 ↗
39. Effects of cardioactive drugs on human induced pluripotent stem cell derived long QT syndrome cardiomyocytes10.1186/s40064-016-1889-y ↗
40. Laminar ventricular myocardium on a microelectrode array-based chip10.1039/C6TB00324A ↗
41. 2D and 3D self-assembling nanofiber hydrogels for cardiomyocyte culture10.1155/2013/285678 ↗
42. The arrhythmogenic effect of self-assembling nanopeptide hydrogel scaffolds on neonatal mouse cardiomyocytes10.1016/j.nano.2014.01.005 ↗
43. Extracellular recordings of bionic engineered cardiac tissue based on a porous scaffold and microelectrode arrays10.1039/c9ay01888c ↗
44. Three-dimensional cardiac microtissues composed of cardiomyocytes and endothelial cells co-differentiated from human pluripotent stem cells10.1242/dev.143438 ↗
45. Miniaturized iPS-cell-derived cardiac muscles for physiologically relevant drug response analyses10.1038/srep24726 ↗
46. Patch clamp apply in cardiomyocytes derived from patient’s iPS cells for individual anticancer therapy
47. Role of hERG potassium channel assays in drug development10.4161/chan.2.2.6004 ↗
48. Field and action potential recordings in heart slices: correlation with established in vitro in vivo models10.1111/j.1476-5381.2011.01775.x ↗
49. A simple vacuum-based microfluidic technique to establish high-throughput organs-on-chip and 3D Cell cultures at the microscale10.1002/admt.201800319 ↗
50. A non-invasive platform for functional characterization of stem-cell-derived cardiomyocytes with applications in cardiotoxicity testing10.1016/j.stemcr.2015.02.007 ↗
51. Generation of spatial-patterned early-developing cardiac organoids using human pluripotent stem cells10.1038/nprot.2018.006 ↗
52. Electrophysiological characterization of drug response in hSC-derived cardiomyocytes using voltage-sensitive optical platforms10.1016/j.vascn.2019.106612 ↗
53. Use of human induced pluripotent stem cell-derived cardiomyocytes to assess drug cardiotoxicity10.1038/s41596-018-0076-8 ↗
54. Heinricher · 2004 · p 1310.1055/b-0034-56090 ↗
55. Tissue engineering of a differentiated cardiac muscle construct10.1161/hh0202.103644 ↗
56. Functional scaffold-free 3D cardiac microtissues: a novel model for the investigation of heart cells10.1152/ajpheart.00743.2011 ↗
57. QT assessment in early drug development: the long and the short of it10.3390/ijms20061324 ↗
58. Proarrhythmia risk prediction using human induced pluripotent stem cell-derived cardiomyocytes10.1016/j.jphs.2018.02.005 ↗
59. Action potential-based MEA platform for in vitro screening of drug-induced cardiotoxicity using human iPSCs and rat neonatal myocytes10.1016/j.vascn.2017.05.003 ↗
60. Hyperphysiological compression of articular cartilage induces an osteoarthritic phenotype in a cartilage-on-a-chip model
61. Comprehensive in vitro Proarrhythmia Assay, a novel in vitro in silico paradigm to detect ventricular proarrhythmic liability: a visionary 21st century initiative10.1517/14740338.2014.915311 ↗
62. The duration of systole in an electrocardiogram in normal humans and in patients with heart disease10.1046/j.1542-474X.2003.08413.x ↗
63. Design and implementation challenges of microelectrode arrays: a review10.4236/msa.2013.48059 ↗
64. Interpretation of field potentials measured on a multi electrode array in pharmacological toxicity screening on primary and human pluripotent stem cell-derived cardiomyocytes10.1016/j.bbrc.2017.01.151 ↗
65. Design and validation of a microfluidic device for blood–brain barrier monitoring and transport studies10.1088/1361-6439/aaa816 ↗